Cited by 1,296HIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV Research and Treatment

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Open access

Marrazzo, Jeanne M., Ramjee, Gita, Richardson, Barbra A., Gomez, Kailazarid, Mgodi, Nyaradzo, Nair, Gonasagrie, Palanee, Thesla, Nakabiito, Clemensia, van der Straten, Ariane, Noguchi, Lisa, Hendrix, Craig W., Dai, James Y., Ganesh, Shayhana, Mkhize, Baningi, Taljaard, Marthinette, Parikh, Urvi M., Piper, Jeanna, Mâsse, Benoît, Grossman, Cynthia, Rooney, James, Schwartz, Jill L., Watts, Heather, Marzinke, Mark A., Hillier, Sharon L., McGowan, Ian M., Chirenje, Z. Mike·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1402269PMC PMC4341965

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1402269

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citation
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647

Flagged first, then by citations

Show all 19 references

Sorted by citations

Items 601–700 of 999

A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir
Thurman, A. R., Ouattara, L. A., Yousefieh, N., Anderson, P. L., Bushman, L. R., Fang, X., Hanif, H., Clark, M. R., Singh, O., & Doncel, G. F. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1130101 · Cited by 17
Sex Differences in HIV Infection
Altfeld, M. A., & Scully, E. P. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_3 · Cited by 15
The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment
Seay, K., Khajoueinejad, N., Zheng, J. H., Kiser, P. F., Ochsenbauer, C., Kappes, J. C., Herold, B. C., & Goldstein, H. (2015) · Journal of Virology · doi:10.1128/jvi.01326-15 · Cited by 15
Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection
Kalapila, A. G., & Marrazzo, J. M. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.03.013 · Cited by 17
PrEP Implementation Science: State-of-the-Art and Research Agenda
Cáceres, C. F., Mayer, K. H., Baggaley, R. C., & O’Reilly, K. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.4.20527 · Cited by 18
Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women
McGowan, I., Cranston, R., Mayer, K. H., Febo, I. L., Duffill, K., Siegel, A., Engstrom, J. C., Nikiforov, A., Park, S., Brand, R. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158310 · Cited by 15
A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability
Weld, E. D., Hiruy, H., Guthrie, K. M., Fava, J. L., Vargas, S. E., Buckheit, K. W., Buckheit, R. W., Spiegel, H. M. L., Breakey, J., Fuchs, E. J., et al. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0167 · Cited by 15
Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial
Husnik, M. J., Brown, E. R., Marzinke, M. A., Livant, E., Palanee‐Phillips, T., Hendrix, C. W., Kiweewa, F. M., Nair, G., Soto-Torres, L. E., Schwartz, K. D., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001503 · Cited by 15
What Can Urine Tell Us About Medication Adherence?
Anderson, P. L. (2018) · EClinicalMedicine · doi:10.1016/j.eclinm.2018.09.003 · Cited by 15
Sex Differences in HIV Infection: Mystique Versus Machismo
Scully, E. P. (2018) · Pathogens and Immunity · doi:10.20411/pai.v3i1.238 · Cited by 15
Summary of German‐Austrian HIV PrEP guideline
Spinner, C., Lang, G. K., Boesecke, C., Jessen, H. K., Schewe, K., & 2018, T. G. P. C. C. M. (2019) · HIV Medicine · doi:10.1111/hiv.12724 · Cited by 15
Unspeakable PrEP: a qualitative study of sexual communication, problematic integration, and uncertainty management among men who have sex with men in Taiwan
Huang, P.-Y., Wu, H., Strong, C., Jan, F.-M., Mao, L.-W., Ko, N., Li, C., Cheng, C., & Ku, S. W. (2019) · Journal of Applied Communication Research · doi:10.1080/00909882.2019.1693608 · Cited by 17
Topical microbicides for preventing sexually transmitted infections
Obiero, J. A., Ogongo, P., Mwethera, P. G., & Wiysonge, C. S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007961.pub3 · Cited by 16
Medication Non-adherence and Condomless Anal Intercourse Increased Substantially During the COVID-19 Pandemic Among MSM PrEP Users: A Retrospective Cohort Study in Four Chinese Metropolises
Gao, Y., Hu, Q., Leuba, S. I., Jia, L., Wang, H., Huang, X., Chen, Y., Wang, H., Zhang, J., Chu, Z., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.738541 · Cited by 15
Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women
Hynes, J. S., Sheth, A. N., Lathrop, E., Sales, J. M., & Haddad, L. B. (2019) · Journal of Women s Health · doi:10.1089/jwh.2018.7001 · Cited by 15
Drug stability and product performance characteristics of a dapivirine-releasing vaginal ring under simulated real-world conditions
Murphy, D. J., McCoy, C. F., Boyd, P., Derrick, T., Spence, P., Devlin, B., & Malcolm, K. R. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.05.027 · Cited by 15
Views among Malawian women about joining HIV prevention clinical trials when pregnant
Sullivan, K., Mtande, T., Jaffe, E., Rosenberg, N. E., Zimba, C. C., Hoffman, I., Little, M., Faden, R., & Lyerly, A. D. (2020) · AIDS Research and Therapy · doi:10.1186/s12981-020-00271-6 · Cited by 15
Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial
Dezzutti, C. S., Richardson‐Harman, N., Rohan, L. C., Marzinke, M. A., Hoesley, C. J., Panther, L., Johnson, S., Nuttall, J. P., Nel, A. M., & Chen, B. A. (2016) · Medicine · doi:10.1097/md.0000000000004174 · Cited by 14
Perceived risk versus objectively measured risk of HIV acquisition: a cross-sectional study among HIV-negative individuals in Serodiscordant partnerships with clients attending an Urban Clinic in Uganda
Tugume, L., Muwonge, T. R., Nakku-Joloba, E., Isunju, J. B., & Kiweewa, F. M. (2019) · BMC Public Health · doi:10.1186/s12889-019-7929-0 · Cited by 14
A novel “HIV salience and Perception” scale is associated with PrEP dispensing and adherence among adolescent girls and young women in Kampala, Uganda
Velloza, J., Mujugira, A., Muwonge, T. R., Boyer, J., Nampewo, O., Badaru, J., Ssebuliba, T., Stalter, R. M., Stein, G., Baeten, J. M., et al. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03762-x · Cited by 14
Interrogating the promise of long-acting HIV pre-exposure prophylaxis
Pike, C., & Bekker, L. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.11.003 · Cited by 14
Adolescent and young adult research across the HIV prevention and care continua: an international programme analysis and targeted review
Calabrese, S., Perkins, M., Lee, S., Allison, S. M., Brown, G., Jean‐Philippe, P., Chakhtoura, N. A., Moye, J., & Kapogiannis, B. G. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26065 · Cited by 14
Dispelling myths and focusing on notable concepts in HIV pathogenesis
Levy, J. A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.004 · Cited by 14
The Art of HIV Elimination: Past and Present Science
Iwuji, C. C., McGrath, N. M., & de Oliveira, T. (2015) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000525 · Cited by 14
Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine
Koss, C. A., Liu, A., Castillo‐Mancilla, J., Bacchetti, P., McHugh, C., Kuncze, K., Morrow, M., Louie, A., Seifert, S. M., Okochi, H., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001935 · Cited by 14
Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE
Mensch, B., Richardson, B. A., Husnik, M. J., Brown, E. R., Kiweewa, F. M., Mayo, A., Baeten, J. M., Palanee‐Phillips, T., van der Straten, A., & for the MTN-020/ASPIRE study team (2018) · AIDS and Behavior · doi:10.1007/s10461-018-2261-8 · Cited by 14
Increases in HIV Incidence Following Receptive Anal Intercourse Among Women: A Systematic Review and Meta-analysis
Stannah, J., Silhol, R., Elmes, J., Owen, B. N., Shacklett, B. L., Anton, P. A., McGowan, I., van der Straten, A., Dimitrov, D., Baggaley, R. F., et al. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02651-0 · Cited by 17
Topical delivery of long-acting antiretrovirals to prevent HIV acquisition
Palanee‐Phillips, T., & Baeten, J. M. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000598 · Cited by 14
The Effect of PrEP Use Disclosure on Adherence in a Cohort of Adolescent Girls and Young Women in South Africa
Giovenco, D., Pettifor, A. E., Powers, K. A., Hightow‐Weidman, L., Pence, B. W., Edwards, J. K., Gill, K., Morton, J. F., van der Straten, A., Celum, C., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03455-x · Cited by 14
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men
Buchbinder, S., Siegler, A. J., Coleman, K., Vittinghoff, E., Wilde, G., Lockard, A., Scott, H. M., Anderson, P. L., Laborde, N. D., van der Straten, A., et al. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03805-3 · Cited by 14
Perceptions among Dutch men who have sex with men and their willingness to use rectal microbicides and oral pre-exposure prophylaxis to reduce HIV risk – a preliminary study
Marra, E., & Hankins, C. A. (2015) · AIDS Care · doi:10.1080/09540121.2015.1069785 · Cited by 14
Acceptability and Feasibility of Self-Collecting Biological Specimens for HIV, Sexually Transmitted Infection, and Adherence Testing Among High-Risk Populations (Project Caboodle!): Protocol for an Exploratory Mixed-Methods Study
Sharma, A., Stephenson, R. B., Sallabank, G., Merrill, L., Sullivan, S. P., & Gandhi, M. (2019) · JMIR Research Protocols · doi:10.2196/13647 · Cited by 14
Preferences and Acceptability of Vaginal Delivery Forms for HIV Prevention Among Women, Male Partners and Key Informants in South Africa and Zimbabwe: Qualitative Findings
Musara, P., Milford, C., Shapley‐Quinn, M. K., Weinrib, R., Mutero, P., Odoom, E., Mgodi, N. M., Chirenje, Z. M., Hanif, H., Clark, M. R., et al. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-02949-4 · Cited by 14
Genital Mucosal Drug Concentrations and anti-HIV Activity in Tenofovir-Based PrEP Products: Intravaginal Ring vs. Oral Administration
Ouattara, L. A., Thurman, A. R., Jacot, T. A., Cottrell, M. L., Sykes, C., Blake, K., Fang, X., Ju, S., Vann, N. C., Schwartz, J. L., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002820 · Cited by 14
Cross‐sectional trends in HIV prevalence among pregnant women in Botswana: an opportunity for PrEP?
Kapoor, A. K., Mussa, A., Diseko, M., Mayondi, G. K., Mabuta, J., Mmalane, M. O., Makhema, J. M., Morroni, C., Lockman, S., Zash, R., et al. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25892 · Cited by 13
Intimate Partner Violence and Willingness to Use Pre-Exposure Prophylaxis Among Men Who Have Sex With Men in Chengdu, China
Guo, P., Hou, F., Cao, W., Guo, V. Y., Wei, D., Li, J., & Hao, Y. (2022) · Journal of Interpersonal Violence · doi:10.1177/08862605221127197 · Cited by 13
Factors associated with retention on pre-exposure prophylaxis among female sex workers in Kigali, Rwanda
Mubezi, S., Rwibasira, G. N., Uwineza, J., Kayisinga, J. D. D., Wandera, M. G., Malamba, S. S., Mayora, C., & Matovu, J. K. B. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002524 · Cited by 13
The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview
Flohic, E. L., Vrijens, B., & Hiligsmann, M. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16089 · Cited by 13
HIV Pre-Exposure Prophylaxis
Liégeon, G., Delaugerre, C., & Molina, J. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.04.003 · Cited by 14
The influence of social constructs of hegemonic masculinity and sexual behaviour on acceptability of vaginal microbicides in Zambia
Mweemba, O., Dixey, R., Bond, V. A., & White, A. (2017) · Global Public Health · doi:10.1080/17441692.2017.1337800 · Cited by 13
Polymer Gels in Vaginal Drug Delivery Systems
Veiga, M.-D., Ruíz, R., Martín-Illana, A., Notario-Pérez, F., & Cazorla-Luna, R. (2018) · Gels horizons: from science to smart materials · doi:10.1007/978-981-10-6083-0_8 · Cited by 13
Geographical-level contributions of risk factors for HIV infections using generalized additive models: results from a cohort of South African women
Wand, H. C., Dassaye, R., Reddy, T., Yssel, J. D., & Gita Ramjee, H. (2018) · AIDS Care · doi:10.1080/09540121.2018.1556382 · Cited by 13
Qualitative Perceptions of Dapivirine VR Adherence and Drug Level Feedback Following an Open-Label Extension Trial
Naidoo, K., Mansoor, L. E., Katz, A. W. K., Garcia, M., Kemigisha, D., Morar, N. S., Zimba, C. C., Chitukuta, M., Reddy, K., Soto-Torres, L. E., et al. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002590 · Cited by 13
Digital directly observed therapy to monitor adherence to medications: a scoping review
Stoner, M. C. D., Maragh‐Bass, A. C., Sukhija-Cohen, A. C., & Saberi, P. (2022) · HIV Research & Clinical Practice · doi:10.1080/25787489.2022.2103512 · Cited by 13
Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates
Leyva, F. J., Fuchs, E. J., Bakshi, R. P., Carballo‐Diéguez, A., Ventuneac, A., Chen, Y., Caffo, B. S., Du, Y., Torbenson, M. S., Li, L., et al. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0086 · Cited by 13
Evaluation of Sexual Risk Behavior Among Study Participants in the TDF2 PrEP Study Among Heterosexual Adults in Botswana
Gust, D. A., Soud, F., Hardnett, F. P., Malotte, C. K., Rose, C. E., Kebaabetswe, P. M., Makgekgenene, L., Henderson, F. L., Paxton, L. A., Segolodi, T. M., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001143 · Cited by 13
Dealing with pre-exposure prophylaxis-associated condom migration: changing the paradigm for men who have sex with men
Crosby, R. A. (2016) · Sexual Health · doi:10.1071/sh16128 · Cited by 13
Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions
McNicholl, J. M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1231258 · Cited by 13
Convergence for Translation: Drug‐Delivery Research in Multidisciplinary Teams
Traverso, G., Kirtane, A. R., Schoellhammer, C. M., & Langer, R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201712512 · Cited by 13
Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003)
Chirenje, Z. M., Gundacker, H. M., Richardson, B. A., Rabe, L. K., Gaffoor, Z., Nair, G., Mirembe, B. G., Piper, J. M., Hillier, S. L., & Marrazzo, J. M. (2017) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000568 · Cited by 13
Measuring sexual behaviour in Malawi: a triangulation of three data collection instruments
Desmond, N., Nagelkerke, N. J. D., Lora, W., Chipeta, E. K., Sambo, M., Kumwenda, M., Corbett, E. L., Taegtmeyer, M., Seeley, J., Lalloo, D. G., et al. (2018) · BMC Public Health · doi:10.1186/s12889-018-5717-x · Cited by 13
A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV
Cranston, R., Dezzutti, C. S., Siegel, A., Engstrom, J. C., Shetler, C., Richardson‐Harman, N., Abebe, K. Z., Back, D. J., Else, L., Egan, D., et al. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0265 · Cited by 13
Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women
Gustin, A. T., Cromarty, R. T., Schifanella, L., & Klatt, N. R. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101482 · Cited by 16
Genital microbiota of women using a 90 day tenofovir or tenofovir and levonorgestrel intravaginal ring in a placebo controlled randomized safety trial in Kenya
Dabee, S., Mugo, N., Mudhune, V., McLellan–Lemal, E., Peacock, S., O’Connor, S., Njoroge, B. W., Nyagol, B., Thurman, A. R., Ouma, E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13475-9 · Cited by 13
Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
Kojima, N., & Klausner, J. D. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv221 · Cited by 12
Determinants of HIV Preexposure Prophylaxis Adherence Among Female Sex Workers in a Demonstration Study in Cotonou, Benin: A Study of Behavioral and Demographic Factors
Mboup, A., Diabaté, S., Béhanzin, L., Guédou, F. A., Zannou, D. M., Kêkê, R. K., Bachabi, M., Gangbo, F. A., Marzinke, M. A., Hendrix, C. W., et al. (2021) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000001373 · Cited by 12
A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in Côte d’Ivoire: the ANRS 12381 PRINCESSE project
Becquet, V., Nouaman, M., Plazy, M., Agoua, A., Zébago, C., Dao, H., Montoyo, A., Jary, A., Coffie, P. A., Eholié, S. P., et al. (2021) · BMC Public Health · doi:10.1186/s12889-021-12235-0 · Cited by 15
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis
Karim, S. S. A., Baxter, C., & Karim, Q. A. (2022) · Antiviral Therapy · doi:10.1177/13596535211067589 · Cited by 12
The Impact of Over-The-Counter Lactic Acid Containing Vaginal Gels on the Integrity and Inflammatory State of the Vaginal Epithelium in vitro
Tyssen, D. P., Hearps, A. C., Guntur, K., Masson, L., Cook, S., Moulton, S. E., Ravel, J., Bradshaw, C. S., Ayehunie, S., & Tachedjian, G. (2022) · Frontiers in Reproductive Health · doi:10.3389/frph.2022.915948 · Cited by 12
A Text Messaging–Based Support Intervention to Enhance Pre-exposure Prophylaxis for HIV Prevention Adherence During Pregnancy and Breastfeeding: Protocol for a Randomized Controlled Trial
Mogaka, J., Otieno, F., Akim, E., Beima-Sofie, K. M., Dettinger, J., Gómez, L., Marwa, M. M., Odhiambo, B., Ngure, K., Ronen, K., et al. (2023) · JMIR Research Protocols · doi:10.2196/41170 · Cited by 13
Antibodies for HIV prevention in young women
Karim, S. S. A., Karim, Q. A., & Baxter, C. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000147 · Cited by 12
Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City
Watnick, D. L., Keller, M. J., Stein, K., & Bauman, L. J. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1962-8 · Cited by 12
Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells
Shen, Z., Rodríguez‐García, M., Patel, M. V., Bodwell, J. E., Kashuba, A. D. M., & Wira, C. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-18078-3 · Cited by 12
Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study
Chappell, C. A., Harkoo, I., Szydlo, D. W., Bunge, K. E., Singh, D., Nakabiito, C., Mhlanga, F., Kamira, B., Piper, J. M., Balkus, J. E., et al. (2019) · Contraception · doi:10.1016/j.contraception.2019.06.006 · Cited by 12
Effectiveness of vaginal microbicides in preventing HIV transmission
Musekiwa, A., Fernando, N. B., & Abariga, S. A. (2020) · Tropical Medicine & International Health · doi:10.1111/tmi.13401 · Cited by 12
Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling
Rajoli, R. K. R., Demkovich, Z. R., Flexner, C. W., Owen, A., & Siccardi, M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00155-20 · Cited by 12
Influence of Plasticizers on the pH-Dependent Drug Release and Cellular Interactions of Hydroxypropyl Methylcellulose/Zein Vaginal Anti-HIV Films Containing Tenofovir
Notario-Pérez, F., Cazorla-Luna, R., Martín-Illana, A., Galante, J., Ruíz, R., Sarmento, B. F. C. C., das Neves, J., & Veiga, M.-D. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.0c01609 · Cited by 12
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis
Sekabira, R., McGowan, I., Yuhas, K., Brand, R. M., Marzinke, M. A., Manabe, Y. C., Frank, I., Eron, J. J., Landovitz, R. J., Anton, P. A., et al. (2021) · AIDS · doi:10.1097/qad.0000000000002907 · Cited by 12
Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring
Stoner, M. C. D., Browne, E. N., Gundacker, H. M., Hawley, I., Chen, B. A., Hoesley, C. J., Scheckter, R., Piper, J. M., Singh, D., Song, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263664 · Cited by 12
Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
Donnell, D. J., Gao, F., Hughes, J. P., Hanscom, B. S., Corey, L., Cohen, M. S., Edupuganti, S., Mgodi, N. M., Rees, H., Baeten, J. M., et al. (2023) · Journal of the International AIDS Society · doi:10.1002/jia2.26118 · Cited by 12
Negotiating the use of female-initiated HIV prevention methods in a context of gender-based violence: the narrative of rape
Hartmann, M., Montgomery, E., Stadler, J., Laborde, N. D., Magazi, B., Mathebula, F., & van der Straten, A. (2015) · Culture Health & Sexuality · doi:10.1080/13691058.2015.1101786 · Cited by 12
Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response
Heydarchi, B., Gonelli, C. A., Muller, B. D., Mackenzie, C., Khoury, G., Lichtfuss, M., Rawlin, G., & Purcell, D. F. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157353 · Cited by 12
Lubricant Use and Rectal Chlamydial and Gonococcal Infections Among Men Who Engage in Receptive Anal Intercourse
Maierhofer, C., Exten, C. L., Wang, S.-H., Fields, K. S., Ervin, M., & Turner, A. N. (2016) · Sexually Transmitted Diseases · doi:10.1097/olq.0000000000000463 · Cited by 12
M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures
Musumeci, G., Bon, I., Lembo, D., Cagno, V., Re, M. C., Signoretto, C., Diani, E., Lopalco, L., Pastori, C., Martin, L., et al. (2017) · Scientific Reports · doi:10.1038/srep41018 · Cited by 12
Achieving the Optimal Vaginal State: Using Vaginal Products and Study Gels in Uganda, Zimbabwe, and South Africa
Duby, Z., Mensch, B., Hartmann, M., Montgomery, E., Mahaka, I. C., Bekker, L., & van der Straten, A. (2017) · International Journal of Sexual Health · doi:10.1080/19317611.2017.1297754 · Cited by 12
Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017
on behalf of the MTN-017 Protocol Team, Balán, I. C., Giguere, R., Brown, W., Carballo‐Diéguez, A., Horn, S., Hendrix, C. W., Marzinke, M. A., Ayudhya, R. P. K. N., Patterson, K., et al. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1955-7 · Cited by 12
The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue
Nicol, M. R., Brewers, L. M., Kashuba, A. D. M., & Sykes, C. (2017) · AIDS · doi:10.1097/qad.0000000000001678 · Cited by 12
Social harms in female-initiated HIV prevention method research
Montgomery, E., Roberts, S. T., Nel, A. M., Malherbe, M., Torjesen, K., Bunge, K. E., Singh, D., Baeten, J. M., Marrazzo, J. M., Chirenje, Z. M., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002346 · Cited by 12
Baseline Predictors of High Adherence to a Coitally Dependent Microbicide Gel Based on an Objective Marker of Use: Findings from the Carraguard Phase 3 Trial
Friedland, B., Stoner, M. C. D., Chau, M. M., Plagianos, M. G., Govender, S. N., Morar, N. S., Altini, L., Skoler-Karpoff, S., Ahmed, K., Gita Ramjee, H., et al. (2015) · AIDS and Behavior · doi:10.1007/s10461-015-1123-x · Cited by 12
Cost-Effectiveness of Interventions to Prevent HIV Acquisition
Garnett, G. P., Krishnaratne, S., Harris, K. L., Hallett, T. B., Santos, M. A., Enstone, J. E., Hensen, B., Dallabetta, G., Revill, P. A., Gregson, S., et al. (2017) · World Bank, Washington, DC eBooks · doi:10.1596/978-1-4648-0524-0_ch7 · Cited by 12
Application of a Body Map Tool to Enhance Discussion of Sexual Behavior in Women in South Africa, Uganda, and Zimbabwe
Naidoo, S., Duby, Z., Hartmann, M., Musara, P., Etima, J., Woeber, K., Mensch, B., van der Straten, A., & Montgomery, E. (2020) · Field Methods · doi:10.1177/1525822x20982082 · Cited by 11
Implementation and Access to Pre-exposure Prophylaxis for Human Immunodeficiency Virus by Men Who Have Sex With Men in Europe
Sepodes, B. M. N., Rocha, J. P., Batista, J., Figueira, M. E., Dráfi, F., & Torre, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.722247 · Cited by 11
Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial
Laurie, C., Tota, J. E., El‐Zein, M., Tellier, P., Coutlée, F., Burchell, A. N., & Franco, E. L. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106560 · Cited by 10
The Role of Families in Adolescent and Young Adults’ PrEP Use
Atujuna, M., Montgomery, E., Hartmann, M., Ndwayana, S., Browne, E. N., Sindelo, S., Bekker, L., & Minnis, A. M. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03514-3 · Cited by 13
Policymakers’ and healthcare providers’ perspectives on the introduction of oral pre-exposure prophylaxis for key populations in Ghana
Nagai, H., Adiibokah, E., Tagoe, H., Tun, W., Pilgrim, N. A., Ankomah, A., Rahman, Y. A. A., Addo, S. A., Atuahene, K., Essandoh, E., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-15871-w · Cited by 12
Event-driven PrEP beyond cisgender men who have sex with men
Irie, W. C., Nicol, M. R., Clement, M. E., Bukusi, E. A., Bekker, L., Molina, J., & Stewart, J. C. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00300-x · Cited by 11
Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development
Friedland, B., Gundacker, H. M., Achilles, S. L., Chen, B. A., Hoesley, C. J., Richardson, B. A., Kelly, C. W., Piper, J. M., Johnson, S., Devlin, B., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0312957 · Cited by 11
Nephrotoxicity during tenofovir treatment: a three-year follow-up study in a Brazilian reference clinic
Neto, L. F. D. S. P., Bassetti, B. R., Fraga, I. H. V., Santos, C. R. O., Ximenes, P. D., & Miranda, A. E. (2015) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2015.09.004 · Cited by 11
Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention
Glaubius, R. L., Parikh, U. M., Hood, G., Penrose, K. J., Bendavid, E., Mellors, J. W., & Abbas, U. L. (2016) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw125 · Cited by 11
Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration
McBride, J. W., Dias, N., Cameron, D., Offord, R. E., Hartley, O., Boyd, P., Kett, V. L., & Malcolm, K. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00965-17 · Cited by 11
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention
Husnik, M. J., Brown, E. R., Dadabhai, S. S., Gaffoor, Z., Jeenarain, N., Kiweewa, F. M., Livant, E., Mansoor, L. E., Mirembe, B. G., Palanee‐Phillips, T., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03231-x · Cited by 11
Oral PrEP Consultations Among Adolescent Girls and Young Women in Kisumu County, Kenya: Insights from the DREAMS Program
Heck, C. J., Mathur, S., Alwang’a, H., Oluoch-Madiang, D., Obanda, R., Owiti, M., & Okal, J. (2022) · AIDS and Behavior · doi:10.1007/s10461-022-03590-z · Cited by 11
Spatial clustering of “measured” and “unmeasured” risk factors for HIV infections in hyper-endemic communities in KwaZulu-Natal, South Africa: results from geoadditive models
Wand, H. C., & Gita Ramjee, H. (2015) · AIDS Care · doi:10.1080/09540121.2015.1096896 · Cited by 11
Recent work on vaginal rings containing antiviral agents for HIV prevention
Spence, P. L., Garg, A. B., Woodsong, C., Devin, B., & Rosenberg, Z. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000157 · Cited by 11
Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression
Romas, L. M., Birse, K., Mayer, K. H., Abou, M., Westmacott, G., Giguere, R., Febo, I. L., Cranston, R., Carballo‐Diéguez, A., McGowan, I., et al. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0381 · Cited by 11
Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection?
Pialoux, G., Delaugerre, C., Cotte, L., Raffi, F., Cua, É., & Molina, J. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.08.029 · Cited by 11
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016
Moreno, S., Antela, A., García, F., del Amo, J., Boix, V., Coll, P., Fortuny, C., Sirvent, J. L. G., Gutiérrez, F., Iribarren, J. A., et al. (2017) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2016.11.016 · Cited by 11
Brief Report: PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships
Pyra, M. N., Haberer, J. E., Heffron, R. A., Kidoguchi, L., Brown, E. R., Bukusi, E. A., Asiimwe, S. B., Celum, C., Katabira, E. T., Mugo, N., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001561 · Cited by 11
Prevention, Partners, and Power Imbalances: Women's Views on How Male Partners Affected Their Adherence to Vaginal Microbicide Gels During HIV Prevention Trials in Africa
Miller, L., Morar, N. S., Kapiga, S., Gita Ramjee, H., & Hayes, R. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002463 · Cited by 11
An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate
McGowan, I., Ayudhya, R. P. K. N., Brand, R. M., Marzinke, M. A., Hendrix, C. W., Johnson, S., Piper, J. M., Holtz, T. H., Curlin, M. E., Chitwarakorn, A., et al. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0115 · Cited by 11

Authors: Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
Affiliations: University of California, San Francisco (US)
Harborview Medical Center (US)
Family Health International 360 (US)
University of Zimbabwe (ZW)
Centre for the AIDS Programme of Research in South Africa (ZA)
University of Pittsburgh (US)
Johns Hopkins University (US)
South African Medical Research Council (ZA)
National Institutes of Health (US)
Eastern Virginia Medical School (US)
ORCID: Marrazzo, Jeanne M.
Richardson, Barbra A.
Gomez, Kailazarid
Mgodi, Nyaradzo
Nair, Gonasagrie
Nakabiito, Clemensia
Noguchi, Lisa
Hendrix, Craig W.
Dai, James Y.
Parikh, Urvi M.
Piper, Jeanna
Mâsse, Benoît
Rooney, James
Watts, Heather
Marzinke, Mark A.
Hillier, Sharon L.
McGowan, Ian M.
Chirenje, Z. Mike
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2015-02-05
Volume: 372
Issue: 6
Pages: 509-518
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1402269
PMC: PMC4341965
OpenAlex: W2044369525
Cited by: 1,296
References: 19
Citations by year: 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
FWCI: 147.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
Funders: National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
Topics: Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords: tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
MeSH terms: Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks